What’s next for Black-tailored prostate cancer risk calculator?

"So, there's a lot of evidence to point to the androgen receptor being an important player in at least developing this disease," says Edward M. Messing, MD.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

Patients who received PUL experienced a greater reduction in inference regarding outdoor entertainment and community activities at 1 month vs WVTT.

Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.

Real-world data showed routine use of darolutamide regimens in community urology practice for patients with metastatic hormone-sensitive prostate cancer.

UGN-101 showed efficacy in a broad population of patients with upper tract urothelial cancer and recurrence-free survival rates were high among patients who responded to UGN-101 induction therapy.